Intensive Care Units (ICU): The clinical pharmacist role to improve clinical outcomes and reduce mortality rate- An undeniable function
Journal Title: Journal of Clinical Intensive Care and Medicine - Year 2017, Vol 2, Issue 1
Abstract
Observing relevant biomedical literature we have see that clinical pharmacist play a crucial role in ICU settings with reducing in mortality rate and improving some clinical outcomes.
Authors and Affiliations
Luisetto M, Ghulam Rasool Mashori
Keywords
Related Articles
- EP ID EP556941
- DOI 10.29328/journal.jcicm.1001010
- Views 21
- Downloads 0
Nursing Care of ICU Patients Lightly Sedated with Dexmedetomidine
Background: Intensive care patients are often in need of sedation to endure being intubated. Light sedation is increasingly common since it has been proved to offer benefits such as faster recovery to patients.
Critical Management of Status Epilepticus
Seizure is clinical manifestation of sudden disruption of the normal electrical activity of cortical neurons. The brain electrical activity is periodically disturbed, alteration in neural cell integrity, increase in firi...
Phenibut Overdose in Combination with Fasoracetam: Emerging Drugs of Abuse
The widespread availability of non-traditional dietary supplements and pharmacologically active substances via the Internet continues to introduce mechanisms for inadvertent toxidromes not commonly seen. Consumers are vi...
Knowledge, attitude and practices associated with diagnosis and management of Skin and Soft Tissue Infections (SSTIs) among Pediatric Residents and Physicians in a Tertiary Hospital in United Arab Emirates (UAE)
Objectives: The study aims to assess the knowledge, attitude and practices of physicians who deal with pediatric age group SSTIs in reference to the Infectious Diseases Society of America (IDSA) guidelines on this regard...
Novel Complication of Nusinersen Treatment: Hyponatremia
There are variations in therapeutic regimens of different liver diseases. The accurate diagnosis ensNusinersen treatment is a novel therapy for spinal muscular atrophy (SMA) type 1; consequently, the adverse reactions of...